ADYA

Adya Bioscience is a San Diego-based biotechnology company focused on the discovery and development of novel small molecule therapeutics targeting deubiquitinating enzymes (DUBs). The company's primary focus is on USP7, a critical enzyme that regulates the stability of various tumor suppressors and oncogenes, making it a high-value target in oncology. Adya's platform leverages deep expertise in DUB biology and medicinal chemistry to create potent and selective inhibitors. Their lead programs are currently in the pre-clinical stage, with potential applications in treating multiple myeloma, prostate cancer, and other solid tumors. The company was founded by industry veterans with extensive experience in drug discovery and development. Adya aims to address unmet medical needs in cancer by developing precision medicines that modulate protein degradation pathways.